During the Track Record Period, we relied heavily on the sales of CF017, with its sales revenue representing 96.2%, 98.4%, 94.5% and 91.6% of our total revenue in 2022, 2023, 2024 and the three months ended March 31, 2025, respectively.
Summary · p. 1
During the Track Record Period, 96.2%, 98.4%, 94.5% and 91.6% of our total revenue in 2022, 2023, 2024 and the three months ended March 31, 2025 was attributable to sales of our CF017.
Summary · p. 15
Currently, we expect that we will have at least five new product approvals and commercially launch these products within the next five years, from 2026 to 2030.
All of our revenue during the Track Record Period was generated from the sales of our nursery products.
Financial Information · p. 319
The revenue growth was primarily driven by increased sales of our core products, such as car seats and strollers, as well as the expansion of our product offerings into pajamas, pillows and baby care products.
Financial Information · p. 319
We have established a proven growth model by initially entering into nursery product segments such as strollers, car seats, cribs and highchairs, that are characterized by product complexity, strong demand and high transaction value.
As of the Latest Practicable Date, we only had one mine, i.e., the Boguty tungsten mine, and our future revenue in the near term is dependent on this mine.
Summary · p. 1
Apart from tungsten ore concentrate, we plan to carry out further processing steps to produce ammonium paratungstate (APT) and tungsten carbide powder (WC) using the net proceeds from the Global Offering.
Communications Platform as a Service, also known as CPaaS, is at the core of our business, accounting for over 80% of our revenue during the Track Record Period.
Summary · p. 1
In 2022, 2023, and 2024, our revenue derived from cloud-based communications services was RMB694.8 million, RMB850.7 million, RMB866.1 million, respectively, which represented 85.8%, 92.9%, and 94.4% of our total revenue for the respective periods.
Financial Information · p. 316
In 2022, 2023, and 2024, our revenue derived from CPaaS represented 78.1%, 85.2%, and 86.8% of our total revenue, respectively.
Our mobility service revenues constituted a significant portion of our total revenues accounting for 97.9%, 96.6% and 92.6% in 2022, 2023, and 2024, respectively.
Summary · p. 17
We expect our mobility service revenue to continue to grow and be a material contributor to our total revenue in the foreseeable future as the shared mobility industry continues to expand and as we implement our growth strategy.
In particular, soy sauce products remain a cornerstone of our product portfolio, and revenue from sales of soy sauce products accounted for the majority of our total revenue during the Track Record Period.
Financial Information · p. 270
In addition, we actively expanded into other product categories, namely oyster sauce products, flavored sauce products and specialty condiment products and others, so as to diversify our product offerings to our customer base.
The long-term life and health insurance products we distributed generated most of our total GWP during the Track Record Period.
Business · p. 240
Long-term life insurance products accounted for 61.5%, 75.6% and 61.7% of the FYP we facilitated in 2022, 2023 and 2024, respectively.
Financial Information · p. 377
Therefore, long-term life insurance and long-term critical illness insurance products bring us a continuous flow of commission cash inflow during the payment period as long as the policyholders meet their payment commitments.
During the Track Record Period, we derived a majority of our revenue from our GASTROClear™ tests and Fortitude™ tests.
Summary · p. 19
Our ability to successfully increase the sales volume and maintain sales price of GASTROClear™ will significantly affect our business and results of operations.
Our revenue derived from sales of gold was 78.5%, 84.6%, 87.6%, 88.3% and 89.4% in 2021, 2022 and 2023 and the nine months ended September 30, 2023 and 2024.
Financial Information · p. 471
As such, fluctuations in gold and non-ferrous metal prices directly affect our results of operations.
A substantial portion of our revenue during the Track Record Period was generated from provision of the System integral software solutions in hospitals, which accounted for 42.1%, 36.1%, 61.3%, 62.3% and 68.0% of our total revenue in 2021, 2022, 2023, and the six months ended June 30, 2023 and 2024, respectively.
Business · p. 351
Building on our early success with respect to cognitive centers, we became the first organizer of a project initiated by the NHC, according to Frost & Sullivan, under which we are tasked with helping to establish cognitive centers in over 2,100 public hospitals across China and promoting the development of cognitive impairment DTx market in China over the next five years.
For FY2021, FY2022, FY2023, 6M2023 and 6M2024, the sales of our algal oil DHA products accounted for approximately 91.9%, 92.7%, 94.7%, 93.5% and 96.2% of our total revenue, respectively.
Summary · p. 1
Subsequent to the Track Record Period, algal oil DHA products remained to be our most important product category in terms of sales for the five months ended 30 November 2024, which constituted approximately 96.2% of our total revenue for the same period.
Throughout the Track Record Period, we primarily derived our revenue from product sales of MAOGEPING, which contributed 96.6%, 98.4%, 99.0%, 99.0% and 99.3% of our total revenue from product sales in 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.
Summary · p. 2
We primarily operate two beauty brands: our flagship brand MAOGEPING and Love Keeps. We offer a selective portfolio of color cosmetics and skincare products under each brand, speaking to different consumer demographics.
We acquired Guyoudao from Hangzhou Huadong Medicine Group Co., Ltd. (杭州華東醫藥集團有限公司) in 2010 recognizing its promising prospects, and it generated a significant portion of our revenue during the Track Record Period.
Summary · p. 1
Because of our professional sales and marketing team and our established sales and distribution network, Guyoudao experienced rapid increase in sales volume and became our major revenue driver during the Track Record Period.
Summary · p. 6
As a result, there were only four commercialized rhBMP-2 products in the Chinese market as of the Latest Practicable Date, with Guyoudao being the earliest and the one with the largest market share, which is 85.5% in 2023.
During the Track Record Period, our revenue was derived from the sales of Utidelone Injection.
Summary · p. 16
Currently, we primarily sell and market Utidelone Injection in China, and for the years ended December 31, 2022, 2023 and the five months ended May 31, 2024, our revenue amounted to RMB32.8 million, RMB66.6 million and RMB28.6 million, respectively.
Business · p. 351
Our Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of our product portfolio.
our revenue from packaged drinking water products increased by 2.7% from RMB6,648.0 million in the six months ended June 30, 2023 to RMB6,828.7 million in the same period of 2024, mainly as a result of increased customer demand for our products, as we enhanced penetration of the sales network and expanded the sales regions for certain products, particularly medium- to large-sized bottled water products, with revenue contribution increased by RMB160.5 million from RMB2,107.4 million in the six months ended June 30, 2023 to RMB2,267.9 million in the same period of 2024.
Summary · p. 23
Our small-sized bottled water products have been the flagship products under our C’estbon brand.
Financial Information · p. 327
In 2021, 2022 and 2023 and the four months ended April 30, 2023 and 2024, revenue generated from sales of medium- to large-sized bottled water products was RMB3,469.2 million, RMB3,962.3 million, RMB4,242.9 million, RMB1,177.1 million and RMB1,258.8 million, respectively, accounting for approximately 32.1%, 33.3%, 34.1%, 32.5% and 33.8% of our revenue generated from packaged drinking water products during the same periods, respectively.
Our revenue from sales of cookware for our branded business amounted to RMB244.7 million, RMB444.6 million, RMB1,237.7 million, RMB220.7 million, and RMB397.4 million in 2021, 2022, and 2023 and for the three months ended March 31, 2023 and 2024, respectively, accounting for 86.4%, 83.8%, 89.7%, 89.5%, and 88.3% of our total revenue from branded business for the same period, respectively.
Financial Information · p. 331
We expect that sales of cookware will continue to contribute the majority of our total revenue from branded business in the foreseeable future.
Financial Information · p. 331
According to the CIC Report, the global cookware industry has experienced consistent growth over the past five years, having increased from US$27.8 billion in 2019 to US$30.9 billion in 2023.
In 2021, 2022 and 2023, we generated revenue of RMB695.1 million, RMB514.9 million and RMB774.0 million from our carpooling marketplace services, respectively, representing 89.0%, 90.5% and 95.0% of our total revenue in the same years, respectively.
Summary · p. 2
We also intend to further capture monetization opportunities along the value chain of China's mobility market, such as the automobile value-added services.
Financial Information · p. 357
Furthermore, our ability to continue to step up our monetization efforts nationwide and explore additional types of service charges is a key factor affecting the revenue generated from our smart taxi services.